Advocacy for alternatives to animal testing in clinical research is pushing the industry away from animal-based endotoxin ...

Experts at Faegre Drinker offer life sciences business planning and risk mitigation strategies to consider in response to ...

Modern drug development approaches that integrate functional plans with larger business goals are needed for success in early ...

Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and ...

On this week's Business of Biotech episode, Yaniv Sneor, founder of the Mid Atlantic Bio Angels and CEO at Native State Therapeutics, explains how life science angel investors evaluate biotech ...

Earnouts have been a part of M&A for decades, with pharmaceutical M&A transactions in particular relying on them. These earnout provisions are typically referred to as “milestone payments” because ...

In the realm of pharmaceutical patent litigation, settlement agreements between branded and generic pharmaceutical companies are frequently used to resolve disputes before, during, and after trials in ...

On this week's Business of Biotech, Michelle Werner, CEO at Alltrna, talks transfer RNA (tRNA) therapy with host Ben Comer and guest co-host Anna Rose Welch, editorial and community director at ...

In the early 1990s, my grandmother’s health and cognitive abilities started to decline rapidly. She showed clear signs of dementia, which was most likely Alzheimer’s disease but never received a ...

They say the mark of intelligence is making the complex simple. By that standard, navigating early commercialization in the pharmaceutical industry is one of the toughest challenges, especially for ...

On today's episode, Tolga Tanguler, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals, talks about commercializing RNAi therapies, how they fit into health insurance reimbursement systems, ...

Electronic Clinical Outcome Assessments (eCOAs) have advanced considerably, yet persistent myths still prevent clinical teams from leveraging their full value. As regulatory expectations evolve and ...